EZH2 and melanoma: In melanoma, dysregulated lipid metabolism, driven by SCD1 overexpression, was shown to blunt the sensitivity to EZH2 inhibitors; the pharmacological inhibition of SCD1 successfully restored drug sensitivity in in vitro and in vivo models.